Page 42 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Neurodegenerative Disorder
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
#AANAM – Disease Severity, Job Loss High in Black RRMS Patients in US
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
email article
Two of the nation s top NIH experts Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and Walter Koroshetz, MD, director of the National Institute of Neurological Disorders and Stroke (NINDS) joined American Academy of Neurology (AAN) science committee leaders in special session about COVID-19 at the AAN annual meeting.
Of particular interest to neurologists were questions about COVID vaccines, nervous system involvement during acute infection, and symptoms like brain fog and fatigue that linger for months. Fauci and Koroshetz touched upon those and other topics. Here are a few highlights of their discussion.
Why the Alterity (ASX:ATH) share price is skyrocketing 42% today
Aaron Teboneras | April 21, 2021 3:56pm |
More on:
One of the best performers on the ASX today is the
At the time of writing, Alterity shares are swapping hands for 4.25 cents apiece, up 41.67%.
What does Alterity do?
Alterity is an Australian biotech company focused on commercialising research into neurodegenerative disorders. These include Parkinsonian movement disorders, Alzheimer’s disease, Huntington disease and others.
The company’s lead candidate ATH434 is currently in development. It aims to block the aggregation of pathological proteins that cause brain degeneration. Current remedies include medications and lifestyle choices to manage symptoms, but there is no treatment to cure the disease.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Kesimpta (ofatumumab) may now be prescribed through the National Health Service (NHS) of England and Wales as an at-home, self-administered treatment for people with relapsing-remitting multiple sclerosis (RRMS) who are either having relapses or have other evidence of MS activity.
A poster presentation at the AAN meeting, based on Phase 3 data in newly diagnosed patients, also showed it effective at preventing disability progression in the absence of a relapse in this group.
The National Institute for Health Care and Excellence (NICE) made the recommendation to include Kesimpta in the NHS, allowing RRMS patients to access it at low and fixed prices, following Kesimpta’s recent approval in the U.K. for relapsing forms of multiple sclerosis (MS).
vimarsana © 2020. All Rights Reserved.